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Prevalence of human papillomavirus DNA in cutaneous neoplasms from
renal allograft recipients supports a possible viral role in tumour
promotion
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C.C. Bird'
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Summary It is well established that renal allograpft recipients (RARs) have an increased incidence of viral
warts and premalignant and malignant cutaneous lesions, and the risk of their development increases in
proportion to duration of graft survival. It has been postulated that, in addition to the effects of prolonged
immunosuppression and previous sun exposure, human papillomaviruses (HPV) may also contribute to the
carcinogenic process. In this study, the prevalence of HPV DNA was examined in a range ofpremalignant and
malignant cutaneous tumours from 50 immunosuppressed patients (47 renal allograft recipients plus three
cardiac allograft recipients) and 56 immunocompetent patients using Southern hybridisation as a low-
stringency screening method and type-specific polymerase chain reaction (PCR) assays for eight HPV types.
The combined results for renal allograft recipients show that HPV DNA was detectable in 79% of viral warts,
42% ofpremalignant keratoses, 33% of intraepidermal carcinomas, 43% of invasive squamous cell carcinomas
and 16% of uninvolved skin specimens (squamous cell carcinomas/renal allograft recipients significantly
different at P <0.05 from uninvolved skin specimens/renal allograft recipients). In immunocompetent patients
the pattern of HPV DNA prevalence was 100% for viral warts; 25% for keratoses, 23% for intraepidermal
carcinomas, 22% for squamous cell carcinomas and 8% for uninvolved skin. No single HPV type
predominated in tumour specimens from either group. More tumours were found to contain HPV DNA by
Southern hybridisation analysis than PCR, indicating the presence of HPV types other than HPV 1, 2, 5, 6, 8,
11, 16 and 18 in some tumours. However, 'low cancer risk' HPV types 1, 2 and 6 as well as 'high cancer risk'
HPV types 5 and 16 were specifically detected by PCR in a small number of neoplasms. These data suggest
that multiple HPV types may contribute to cutaneous neoplasia in RARs and that they appear to act early in
the process of carcinogenesis, perhaps by functioning as tumour promoters via stimulation of cell prolifera-
tion.
Renal transplantation is now a well-established procedure,
with many recipients surviving 20 years or more. However, a
major problem associated with long-term immunosuppression
is the increased prevalence of various malignancies, especially
in skin, anogenital tract and lymphoreticular system (Hoxtell
et al., 1977; Birkeland, 1983; Blohme & Larko, 1984; Sheil et
al., 1985; Shuttleworth et al., 1987; Alloub et al., 1989).
Moreover, renal allograft recipients (RARs) frequently
develop a spectrum of cutaneous complications ranging from
benign viral warts (VWs), to verrucous and actinic keratoses
(Ks) exhibiting varing degrees of dysplasia, culminating in
squamous cell carcinoma (SCC) (Benton et al., 1992). The
prevalence and morbidity of such complications increases the
longer the duration of immunosuppression with a number of
long-standing RARs developing multiple skin tumours (Barr
et al., 1989). In RARs squamous cell cancers outnumber
basal cell cancers (BCCs) by a ratio of 15: 1, a reversal of the
1:5 ratio normally observed in immunocompetent patients.
A number of factors have been implicated in the develop-
ment of skin cancers in RARs. Ultraviolet (UV) radiation is
known to be of considerable importance as the majority of
tumours occur on sun-exposed skin (Blohme & Larko, 1984;
Boyle et al., 1984; Baadsgaard, 1991; Streilein, 1991). The
alteration in cell-mediated immunity brought about by pro-
longed immunosuppressive therapy is thought to be a con-
tributory factor and is associated with an increased incidence
of anogenital cancers and lymphomas as well as skin
tumours (Streilein, 1991). The possible association with
human papillomaviruses (HPVs) is derived indirectly from
observations in the rare, inherited skin disease epidermodys-
plasia verruciformis (EV) (Orth et al., 1979; Orth, 1986). This
disease is characterised by the development of extensive,
persistent infection with unusual HPV types and a predis-
position to cutaneous SCC on light-exposed skin in around
one-third of patients (Pfister et al., 1983a; Fuchs & Pfister,
1990). Although over 20 HPV types have been detected in
benign skin lesions from EV patients, in SCC HPV types 5
and 8 are consistently demonstrated (Orth et al., 1986; Fuchs
& Pfister, 1990). However, in contrast to the HPV types 16
and 18 that are usually integrated in squamous cervical
cancers, the majority of EV-associated SCCs contain HPV 5
or 8 DNA in an episomal form, with integration being a rare
event (Yabe et al., 1989).
There is also some direct evidence to suggest that HPV
may play a part in the development of skin cancers in RARs
(Blessing et al., 1989; Benton et al., 1992). Histologically,
viral warts and keratotic lesions in RARs often exhibit vary-
ing degrees of epidermal dysplasia, while SCCs develop on a
background of verrucous keratoses and may retain HPV-
associated features. However, the detection of HPV DNA in
the cutaneous SCC of RARs has been somewhat controver-
sial, with EV-associated types and a variety of common
cutaneous and genital HPV types being identified in some,
but not all, studies (Lutzner et al., 1980; Van der Leest et al.,
1987; Barr et al., 1989; Rudlinger & Grob, 1989; Dyall-Smith
et al., 1991; Soler et al., 1992).
We report here the results of an investigation in which we
determined, first, the prevalence of HPV DNA in various
cutaneous lesions from RARs and immune-competent
patients (ICPs) by Southern hybridisation analysis with
mixed probes for common cutaneous and EV-associated
HPV types. Second, using type-specific and sensitive PCR
assays we determined the prevalence of the putative
oncogenic HPV types 5 and 8, the more common cutaneous
HPV types 1 and 2 and the common genital HPV types 6, 11,
16 and 18. Finally, we considered whether the pattern of
HPV prevalence in the cutaneous lesions provided clues as to
the stage at which HPV may act in the oncogenic pro-
cess.
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Materials and methods
Patients
Two groups of patients were investigated. The first comprised
47 immunosuppressed patients, 44 RARs plus three cardiac
allograft recipients (mean age 50 years, range 20-71 years),
all of whom received transplants between 1965 and 1992
(mean duration of transplant 10.9 years, range 1-26 years).
Prior to 1984 patients received immunosuppressive therapy
with prednisolone and azathioprine, but since then all new
allograft recipients have been treated with prednisolone and
cyclosporin A, a few subsequently being switched to azathio-
prine. The second patient group comprised 56 immuno-
competent individuals (mean age 66.6 years, range 22-90
years) who were referred for treatment of suspected warts or
skin malignancies. All patients were treated in the Depart-
ment of Dermatology at the Royal Infirmary of Edin-
burgh.
Tissue collection and DNA extraction
Therapeutic skin biopsies were collected from RARs (120 in
all) and ICPs (63). A 6 mm biopsy ofuninvolved, sun-exposed,
forearm skin was also obtained from 19 RARs (some with
and others without skin tumours elsewhere) and 12 healthy
ICPs who volunteered to undergo this procedure. Immedi-
ately following excision, each lesion was bisected
longitudinally with a sterile blade to minimise the risk of
contamination: half was snap frozen in liquid nitrogen prior
to DNA extraction while the remainder was fixed in formalin
or periodate-lysine-paraformaldehyde-dichromate (PLPD)
(Holgate et al., 1986) for histological examination. Frozen
tissue was minced in lysis buffer (50 mM Tris, 50 mM EDTA,
100 mmsodium chloride, 5 mMDTT, 1% SDS, 1.5mg ml'
proteinase K) and DNA extracted using a standard phenol-
chloroform extraction technique (Sambrook et al., 1989).
Histopathology
The cutaneous lesions were assessed for standard mor-
phological features suggestive of actinic damage and for
degrees of dysplasia progressing to intraepidermal and
invasive carcinoma (Blessing et al., 1989). They were desig-
nated as viral warts (VWs), actinic and verrucous keratoses
(AKs and VKs), intraepidermal carcinoma (IEC) and
squamous cell carcinoma (SCC) (Figure 1). VWs showed
architectural symmetry, hypergranulosis and koilocytosis.
Lesions showing double-layered basal budding, basal
hypermelanosis and dysplasia and loss of granular layer with
superficial parakeratosis were classified as actinic keratoses.
Lesions that showed some features suggestive of HPV infec-
tion, but various degrees of basal budding and basal dys-
plasia, were termed verrucous keratoses. IECs exhibited
either full-thickness dysplasia or severe dysplasia in the basal
layer. The designation of SCC was confined to lesions in
which there was evidence of dermal invasion. In some in-
stances, the complex architecture of VKs and the variable
dysplasia made confirmation of invasion difficult so the term
SCC was used only when dermal invasion was unequivocal
(Blessing et al., 1989).
Polymerase chain reaction (PCR)
Oligonucleotide primers, situated in E6, were designed from
published sequence data (Danos et al., 1982; Fuchs et al.,
1986; Zachow et al., 1987; Hirsch-Behnam, 1990) to detect
HPV types 1, 2, 5 and 8 in type-specific assays (Table I).
Primer sequences for HPV types 6, 11, 16 and 18 were
validated in previous studies (Arends et al., 1991). Prior to
amplification with HPV primers, each sample was amplified
with control ras primers to confirm adequate preservation of
DNA (Table I). A 1 fig aliquot ofgenomic DNA was used as
template in a 1001l reaction containing 1 x preprepared
reaction buffer (NBL), 200JAM dNTPs 1 JAM each primer and
0.5 U of Taq polymerase (NBL). PCR cycle conditions used
Figure 1 a, Viral wart exhibiting papilliferous architecture. Inset shows cell vacuolation (koilocytotic change) and cytoplasmic
inclusions at high power. b, Verrucous keratosis with the topography of a viral wart but lacking the cytological features. There is
some irregularity of the basal tongues. c, Verrucous keratosis with widespread dysplasia amounting to intraepidermal carcinoma. d,
Invasive squamous cell carcinoma arising from a surface exophytic verrucous keratosis (haematoxylin and eosin).224 L.A. STARK et al.
Table I HPV primer sequences used to detect HPV types 1, 2, 5 and 8, and K-ras
HPV
type Primer Sequence Position' Product
I p1 AGTCTTATGAGGTACCGGAAATAGAAG 383-409
1 p2 ATGCACTCTTTCTCCGTTTGACACAACCTC 520-490 136 bp
2 p1 ATGGTTTGGAGCTAGAGGATTTGCG 159-183
2 p2 AACTAGTAATGCCTCCTTCTCCTCC 463-438 303 bp
5 p1 CTCTAATACCAAATTCTGTGGCGT 616-640
5 p2 GAGGAACGCCTGGAAGGGAATCTG 894-870 279 bp
8 p1 CGGGCAGGACAAGGCTTCATATTTAGACAC 200-230
8 p2 ACAACAACGACAACACGCAGTAACAAC 420-393 220 bp
K-ras pI GACTGAATATAAACTTGTGG 3-22
K-ras p2 CTCTATTGTTGGATCATATT 111 -92 109 bp
aPosition in HPV genome defined by EMBL/Genebank database.
to amplify HPV types 1, 2, 5 and 8 were as follows: One
cycle of 94°C for 5 min; 30 cycles of 58°C (55°C for HPV 1)
for 2 min, 72°C for 3 min and 94°C for 1 min; and one cycle
of 58°C (55°C for HPV 1) for 2 min and 72°C for 10 min.
Positive (1 pg of purified HPV plasmid DNA instead of
genomic DNA) and negative (template-free) controls were
included with all reactions. Amplified products were
visualised on a 2% Nusieve-Seakem (3:1) agarose gel con-
taining 0.5 igml-' ethidium bromide (Flowgen Instruments,
Kent, UK).
Southern hybridisation analysis
Genomic DNA (8-1Ong) was digested using the restriction
enzyme BamHI (NBL). Following electrophoresis on 8%
agarose gel, DNA was alkaline denatured and transferred on
to charged nylon membrane (Hybond N+, Amersham, Ayles-
bury, UK) according to the manufacturer's instructions.
HPV probe DNA was isolated from vector DNA by diges-
tion with the appropriate restriction enzyme followed by
electrophoresis on a 0.8% low melting temperature agarose
gel. The resulting HPV DNA was purified using Biorad
Prepagene kit (Biorad Laboratories, Richmond, UK) and
25 ng DNA of each HPV type was prepared and labelled
with 32P using the Amersham Multiprime kit as specified by
the manufacturer's instructions. Hybridisation was carried
out at Tm -40°C (55°C) (hybridisation buffer consisted of
6 x SSC, 1% SDS and 0.1 gml-' dextran sulphate) using
mixed HPV probes containing 25ng each of either HPV
types 3, 8 and 13 or HPV types 2, 4 and 12. The minimum
specific activity of all probes was 4-5 x 106 c.p.m. ml-'. All
filters included positive (HPV plasmid DNA) and negative
(placental DNA) controls. Following hybridisation, filters
were washed at low stringency [2 x SSC, 1% SDS, at 55°C
for 30 min (Tm - 35°C)] and exposed to X-ray film initially
for 24 h and subsequently for 3 days. Cases positive for HPV
by this intial screen were further analysed by Southern hy-
bridisation using the restriction enzyme PstI. Filters contain-
ing 50 pg of purified HPV plasmid DNA of types 1, 2, 3, 4,
5, 8, 10, 12, 13, 14, 17, 19 and 20 (Heilman et al., 1980;
Ostrow et al., 1982, 1983; Kremsdorf et al., 1983, 1984;
Pfister et al., 1983a, b; Gassenmaier et al., 1984) mixed with
10gAg of genomic DNA were also made for use in initial
optimisation experiments. The sensitivity of this technique
was investigated by performing Southern hybridisation
analyses on serially diluted HPV 16 plasmid DNA mixed
with a known concentration of genomic DNA.
Results
Prevalence screenfor HPV DNA by Southern hybridisation
Initial experiments indicated that, by using Southern hy-
bridisation with a probe cocktail containing a mixture of
HPV types 3, 8 and 13 at low hybridisation (Tm - 40'C) and
washing (Tm -35°C) stringency, it was possible to detect
HPV types 1, 2, 3, 4, 5, 8, 10, 12, 13, 14, 17, 19 and 20. The
probe cocktail containing HPV types 2, 4 and 12 was also
extensively used, but added little extra information. The
sensitivity of Southern hybridisation analysis was found to be
5 pg of viral DNA in a background of 10 tg of genomic
DNA, equivalent to 0.1 copies per cell.
A total of 108 skin biopsies from RARs, including over 50
IEC and SCC specimens from 16 patients, together with 63
specimens from ICP were analysed by Southern hybridisa-
tion, using the mixed probe cocktail described above to
screen for the presence of HPV DNA. As expected, detection
of HPV DNA was greatest in VWs (64%), but 25% of
keratoses, 24% of IECs and 33% of SCCs from RARs
contained HPV DNA (Figure 2 and Table II). All specimens
from normal skin were negative for HPV DNA. Lesions
from ICPs showed lower HPV DNA prevalence than those
from RARs, except for viral warts, only five of which were
examined from ICPs (Table II). Statistical comparison of the
results for each histological category between RARs, and
ICPs revealed that SCC/RAR differed significantly (P <0.05
by chi-squared test) from SCC/ICP, despite the small
number of ICPs analysed. It should be noted that the two
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Figure 2 Southern hybridisation autoradiograph showing three
HPV DNA-positive specimens, (A) SCC (from patient G), (D)
VW and (F) VW, compared with three HPV DNA-negative
specimens, (B) AK (from patient I who was HPV 16 positive by
PCR), (C) IEC and (E) AK. All specimens were from RARs, and
the size markers are indicated. A probe cocktail of HPV types 3,
8 and 13 was used with BamHI-digested DNA. Track A (which
was negative by PCR) shows evidence of HPV genome integra-
tion within a DNA fragment greater than 12 kb in size. Tracks D
and F show episomal HPV genomes cleaved twice into fragments
of 6 and 2 kb.HPV AND SKIN CARCINOGENESIS IN RAR 225
Table II HPV DNA prevalence detected by Southern hybridisation analysis
Number (%) of lesions positive
Patient group VW K IEC SCC US
RARs 9/14 (64) 6/24 (25) 5/21 (24) 10/30 (33) 0/19 (0)
ICPs 5/5 (100) 1/8 (13) 0/12 (0) 0/9 (0) 0/12 (0)
Chi-squared tests revealed significant differences of P <0.00001 for comparisons of
both VW/RAR with US/RAR and VW/ICP with US/ICP, P <0.025 for comparison of
either K/RAR or IEC/RAR with US/RAR, P <0.005 for SCC/RAR vs US/RAR, and
P <0.05 for SCC/RAR vs SCC/ICP.
RAR, renal allograft recipient; ICP, immunocompetent patient; VW, viral wart; K,
keratosis; IEC, intraepidermal carcinoma; SCC, squamous cell carcinoma; US,
uninvolved, sun-exposed skin.
groups of patients (RARs and ICPs) could not be age mat-
ched for IEC and SCC specimens, as these occurred mostly
in the elderly in the ICP group. However, compared with 0%
prevalence in US/RAR, HPV DNA positivities differed
significantly in SCCs (33%; P<0.005), IECs (24%;
P<0.025), Ks (25%; P<0.025) and VWs (P<0.00001)
within the RAR group.
Restriction pattern analysis suggested that HPV integra-
tion had taken place in a dysplastic VW, an AK and an SCC
(Figure 2) in three separate RARs. When digested with the
single-cut enzyme BamHI, both cases gave multiple restric-
tion fragments, the sum of which was greater than 8 kb, but
dissimilar to the size of multimer episomes. These banding
patterns were reproducible, providing evidence that some
RAR skin lesions contained integrated HPV DNA, but the
numbers of affected lesions were too small to determine
whether integration plays a significant role. The restriction
patterns obtained when HPV-positive cases were further
digested with PstI were dissimilar, indicating that different
HPV types were present in these lesions.
Detection ofspecific HPV types by polymerase chain reaction
The reaction conditions for all primers were optimised to
allow detection of 0.001 pg of episomal HPV DNA in a
background of 10pg of placental DNA, equivalent to 80
copies of HPV or 5 x 10' copies per cell. Each set of
primers was tested against a panel of cloned HPV types 1, 2,
3, 4, 5, 8, 10, 12, 14, 17, 19 and 20, and found to be
absolutely type specific.
A total of 118 specimens from RARs and 48 from ICPs,
were analysed by type-specific PCR for HPV types 1, 2, 5
and 8 (Tables III and IV). In each sample c-Ki-ras sequences
could be detected with appropriate ras primers (data not
shown). Relatively few specimens were positive for HPV
DNA compared with results by Southern hybridisation
analysis. In particular, HPV 5 DNA was only present in a
small number of benign and premalignant lesions from
RARs and ICPs but in no SCCs. HPV 8 DNA was found in
only one SCC from an ICP. HPV 1 and 2 DNA was found
in both benign and malignant lesions from RARs and ICPs
(Tables III and IV). A total of 102 lesions from RARs and
43 from ICPs were further tested for the common genital
HPV types 6, 11, 16 and 18 by type-specific PCR (Tables III
and IV). 'High-risk' HPV 16 DNA was detected in unin-
volved skin from an RAR, and 'low-risk' HPV 6 DNA was
present in an SCC from an RAR. Four VWs from RARs
contained more than one HPV type (5 and 2, 5 and 6, 5 and
11, 2 and 11). Rigorous anti-contamination procedures were
followed throughout (Arends et al., 1991), and there was no
evidence to suggest that any of these positive results were due
to contamination from other sources. Overall there was no
dominant HPV type in any of the histological categories and
the distribution of types was broadly similar for immunosup-
pressed and immunocompetent patients.
Correlation ofHPV DNA detection by Southern hybridisation
and type-specific PCR
Twenty-one specimens of Ks, IECs and SCCs from RARs
exhibited HPV DNA by Southern hybridisation. However,
only three of these were HPV DNA positive by type-specific
PCR (Table V). Likewise, of the 13 specimens of Ks, IECs
and SCCs from RARs that were HPV DNA positive by
Table III HPV type prevalence by type-specific PCR in renal allograft recipients
HPV type and number of positive lesions
Histological Number Number
type of lesion examined 1 2 5 8 examined 6 11 16 18
VW 18 0 4 3 0 14 1 2 0 0
K 26 2 1 1 0 23 0 0 1 0
IEC 24 0 2 1 0 23 0 0 0 0
SCC 31 1 2 0 0 24 1 0 1 0
US 19 0 0 2 0 18 0 0 1 0
VW, viral wart; K, keratosis; IEC, intraepidermal carcinoma; SCC, squamous cell
carcinoma; US, uninvolved, sun-exposed skin.
Table IV HPV type prevalence by type-specific PCR in immunocompetent patients
HPV type and number of positive lesions
Histological Number Number
type of lesion examined 1 2 5 8 examined 6 11 16 18
VW 6 1 1 0 0 5 0 0 0 0
K 8 0 0 1 0 8 0 0 0 0
IEC 13 2 1 1 0 11 0 0 0 0
SCC 9 0 1 0 1 7 0 0 0 0
US 12 0 1 0 0 12 0 0 0 0
VW, viral wart; K, keratosis; IEC, intraepidermal carcinoma; SCC, squamous cell
carcinoma; US, uninvolved, sun-exposed skin.226 L.A. STARK et al.
type-specific PCR, only three were positive by Southern hy-
bridisation analysis (Table V). A combination of both detec-
tion assays resulted in 11/14 (79%) VWs, 10/24 (42%) Ks,
7/21 (33%) IECs, 13/30 (43%) SCCs and 3/19 (16%) USs
from RARs containing HPV DNA (Table VI). The com-
bined results for ICPs gave HPV prevalences of 5/5 (100%)
for VWs, 2/8 (25%) for Ks, 3/13 (23%) for IECs, 2/9 (22%)
for SCCs and 1/12 (8%) for USs. No statistically significant
differences by the chi-squared test were found comparing
HPV prevalence in each histological group between ICPs and
RARs. However, SCCs from RARs showed a significantly
higher HPV prevalence (P<0.05) than uninvolved skin from
RARs. Overall, HPV DNA was detected with greater fre-
quency by Southern hybridisation analysis than by type-
specific PCR (Tables II, III and IV). Some patients showed a
high susceptibility to developing multiple malignant tumours
exhibiting different HPV DNA content (Table V), but there
was no specific pattern ofcombination of HPV types in these
lesions.
Discussion
Prevalence ofHPV DNA in the spectrum ofcutaneous
neoplasia in RAR
Compelling evidence exists of a contributory role for 'high-
risk' genital HPV types 16 and 18 in the development of SCC
of the genital tract (Arends et al., 1990, 1991, 1993; zur
Hausen, 1991; Lorincz et al., 1992). Similarly, in EV the role
of HPV 5 and 8 in the aetiopathogenesis ofcutaneous SCC is
suggested by their presence in over 90% of cancers (Orth et
al., 1979; Orth, 1986). Furthermore, HPV types 5, 8, 16 and
18 can cooperate with activated ras to transform rodent cells
(Watts et al., 1984; Iftner et al., 1988; Fuchs & Pfister, 1990).
By contrast, investigation of the relationship between HPV
and cutaneous cancers in RARs has been inconclusive with
regard to both prevalence and type of HPV DNA detected.
This may be the result ofdifferences in sample size studied or
differences in sensitivity and specificity of the detection
Table V Clinicopathological details of HPV-positive lesions from renal allograft recipients
Patient Graft
(years)/ duration Histological
x (m/f) (years) type of lesion
56m 6 AK (D++)
49m 17 SCC
SCC
57m 12 AK (D++)
SCC
TEC
55m 8 (cardiac) AK (D + +)
36f 21
52m
44m
59m
62m
52m
VK
IEC
VK
SCC
SCC
SCC
IEC
SCC
IEC
SCC
SCC
VW
10
26
13
8
15
SCC
IEC
SCC
SCC
IEC
SCC
IEC
AK (D + +)
VK
VK (D + +)
AK
VK
VK (D +)
Site
Face
Scalp
Ear
Finger
Hand
Ear
Dorsum
hand
Dorsum
hand
Presternal
Thigh
Neck
Chest
Chest
Dorsum
hand
Forearm
Upper
back
Neck
Back
Dorsum
hand
Shoulder
Scalp
Forearm
Scalp
Scalp
Chest
Scalp
Forearm
Forearm
Forearm
Forearm
Forearm
Thigh
HPV type identified
Southern
hybridisation PCR
pos uk neg
pos 2
pos uk neg
pos uk neg
pos uk neg
pos uk neg
pos uk neg
pOS 10"
pos
ND
neg
neg
pos uk
pos uk
neg
pos uk
pos uk
pos uk
neg
pos
neg
pos uk
pos uk
pos uk
pos uk
neg
neg
pos uk
neg
neg
pos uk
neg
neg
5
5
16
2
neg
neg
6
neg
neg
neg
5,11
2
neg
neg
neg
neg
2
16
neg
I
neg
2
AK, actinic keratosis; D +, mild dysplasia; D + +, moderate dysplasia; D + + +, severe dysplasia;
SCC, squamous cell carcinoma; IEC, intraepidermal carcinoma; VK, verrucous keratosis: ND, not
done; uk, unknown; neg, negative. aThe PstI and HindIII restriction digest of this lesion gave identical
restriction fragment patterns to HPV 10 by Southern hybridisation analysis.
Table VI Combined HPV prevalence by Southern hybridisation analysis and
type-specific PCR assays
Number (%) lesions positive
Patient group VW K IEC SCC US
RARs 11/14 (79) 10/24 (42) 7/21 (33) 13/30 (43) 3/19 (16)
ICPs 5/5 (100) 2/8 (25) 3/13 (23) 2/9 (22) 1/12 (8)
Chi-squared tests revealed significant difference of P <0.05 for comparisons of
SCC/RAR with US/RAR, and P = 0.00003 for both VW/RAR vs US/RAR and VW/ICP
vs US/ICP.
I
Age
se;i Code
A
B
B
C
C
C
D
D
E
E
E
E
E
E
E
F
F
F
F
F
G
G
G
G
G
H
I
I
J
J
J
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methods employed (Lutzner et al., 1980, 1983; Rudlinger et
al., 1986; Jablonska et al., 1987; Van der Leest, 1987; Barr et
al., 1989; Blessing et al., 1989; Rudlinger & Grob, 1989;
Euvrard et al., 1991). An additional factor in some studies
may be the inclusion of a large proportion of patients who
seem to be at exceptionally high risk of developing multiple
and widespread premalignant and malignant cutaneous
lesions with increased HPV DNA content (Barr et al., 1989).
To overcome some of these problems we have studied a
large, unselected series of RARs using both Southern hy-
bridisation and type-specific PCR techniques.
The prevalence of HPV DNA was closely similar through-
out the spectrum of cutaneous neoplasia in RARs: 42% of
keratoses, 33% of IECs and 43% of SCCs contained HPV
DNA, but only 16% of uninvolved skin was positive (Table
VI), not dissimilar to some other reports (Soler et al., 1992).
This pattern differs from that found in cervical neoplasia in
which the prevalence of HPV (of specific 'high-risk' types)
increases throughout the cervical intraepithelial neoplasia
spectrum (Stanley, 1990; Arends et al., 1991, 1993; Lorincz et
al., 1992). These findings suggest that, if HPV play a role in
cutaneous neoplasia of RARs, this must involve the early
stages of the neoplastic process. One hypothesis is that HPVs
may act as tumour promoters by stimulating cell prolifera-
tion. Thus, HPV may provide a stimulus analogous to that
of phorbol esters in traditional rodent skin carcinogenesis
models, in which promotion of cell proliferation fixes irrever-
sibly any genetic mutations induced by initiating agents such
as chemical carcinogens or UV light. The role of promoter
for HPV was previously suggested by zur Hausen (1982), and
the ability to induce keratinocyte proliferation is common to
the many different types of common cutaneous and EV-
associated HPV, as evidenced by the variety of warts that
they cause. This hypothesis is supported by the clinico-
pathological observations that RARs frequently exhibit
extensive warts and verrucous keratoses, as well as malignant
tumours: these lesions form a seamless spectrum of his-
tological change, with many keratoses (actinic and verrucous)
showing dysplasia, and both IECs and SCCs retaining viral
features. Furthermore, these immunosuppressed patients
appear to have relatively high background levels of HPV,
indicated by our findings that 3 out of 19 (16%) biopsies
from the apparently uninvolved skin of RARs contained
HPV DNA, in two cases HPV 5 DNA and in one HPV 16
DNA. Such a background level of HPV infection of skin, in
the presence of long-term immunosuppression that is likely to
permit viral persistence over a prolonged period, together
with sun-induced DNA damage, may give rise to conditions
conducive to tumour induction. Moreover, the usual 1:5
ratio of SCC-BCC is reversed in RARs to 15:1, suggesting
that HPVs encourage squamous rather than basal cell neo-
plastic differentiation.
Specific HPV typesfound in cutaneous neoplasms in RAR
In this study we were not always able to characterise fully the
HPV types found by Southern hybridisation analysis. How-
ever, the results of type-specific PCR analysis indicate that
only a small proportion of lesions contained HPV 5 or 8
DNA. This is in contrast to previous findings from SE
Scotland (Barr et al., 1989), where 15 out of 25 SCCs were
found to contain HPV5 or 8 DNA. That study used mostly
dot blotting to detect HPV 5 or 8 DNA, which does not
exclude the possibility of cross-hybridisation with other EV-
associated HPV types. Moreover, all 15 positive specimens in
that study came from four patients at exceptionally high risk
of development of cutaneous lesions, each of whom had
multiple SCCs. The balance of evidence now suggests that
HPV 5 and 8 DNA is found relatively infrequently in
tumours from RARs (Lutzner et al., 1980, 1983; Rudlinger et
al., 1986; Van der Leest, 1987; Soler et al., 1992).
It is of interest that we found both HPV 1 and 2 DNA by
PCR in a small number of SCCs in this series. These HPV
types were previously considered to be non-transforming, and
usually associated with benign skin warts. Recent work has
also emphasised the importance of extending investigations
of HPV content to include the anogenital HPV types (Ostrow
et al., 1987, 1989; Stone et al., 1987; Rudlinger et al., 1989;
Eliezri et al., 1990; Ashinoff et al., 1991). Two positive SCCs
in the present study, one containing HPV 6 and the other
HPV 16 DNA, both came from a female RAR who in
addition to multiple cutaneous SCCs has developed SCCs of
cervix, vulva and anal canal. HPV 16 DNA has also been
detected in her genital tumours. Overall, from the present
investigation using both Southern hybridisation and PCR,
the emerging pattern of HPV type prevalence is one of
involvement by multiple HPV types.
Some cases found to contain HPV sequences by PCR
could not be confirmed by Southern hybridisation analysis,
indicating that in many cases copy numbers of HPV genomes
were too low to be detected by Southern analysis. Not sur-
prisingly, the absolutely type-specific PCR assays for HPV 1,
2, 5, 6, 8, 11, 16 and 18 did not detect other HPV types
found by Southern hybridisation. In a pilot study applying a
consensus PCR assay (Manos et al., 1989), primarily
designed to detect genital HPV types, the common cutaneous
and EV-associated HPV types were poorly detected even
when using cloned HPV plasmid DNA as template (unpub-
lished data). Thus, it is possible that this and other studies
have underestimated the true HPV prevalence in cutaneous
neoplasms in RARs, owing to a combination of a wide
variety of HPV types involved and low copy number of HPV
genomes.
The overall pattern found in this study is of similar HPV
prevalence throughout the spectrum of cutaneous neoplasia
in RARs. Furthermore, studies of the prevalence of
accurately typed specific HPV have shown that no single
HPV type predominates in cutaneous lesions in RARs with
multiple HPV types being detected. At a practical level, these
data challenge the necessity to systematically type HPV DNA
found in cutaneous lesions in RARs. Our observations are
consistent with the hypothesis that in RARs multiple HPV
types play a role in carcinogenesis by promotion of cell
proliferation, and this hypothesis merits further testing.
We would like to thank the Scottish Home and Health Department
and Cancer Research Campaign for funding this research, Robert
Morris for technical advice, Jill Bubb and Andrew Wyllie for useful
discussions and Miss Jenni Westwater for secretarial assistance.
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